thymalfasin and Pneumonia--Viral

COVID-19 is known for its magical infectivity, fast transmission and high death toll based on the large number of infected people. From the perspective of the clinical manifestation, autopsy examination and pathophysiology, the essence of COVID-19 should be viewed as a sepsis induced by viral infection, and has the essential characteristics as sepsis induced by other pathogens. Therefore, in addition to etiological and supportive treatment, immunomodulatory therapy is also appropriate to severe COVID-19. Although there is still a lack of consensus on immunotherapy for sepsis so far, relatively rich experiences have been accumulated in the past decades, which will help us in the treatment of severe COVID-19. This article will elaborate immunotherapy of sepsis, though it may not be consistent.

Topics: Adrenal Cortex Hormones; Betacoronavirus; Coronavirus Infections; COVID-19; Glycoproteins; Humans; Immunologic Factors; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sepsis; Thymalfasin

Topics: Adolescent; Adult; Aged; Antibodies, Viral; Ascorbic Acid; Betacoronavirus; China; Coronavirus Infections; COVID-19; Cross-Sectional Studies; Female; Humans; Hydroxychloroquine; Immunologic Factors; Male; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index; Thymalfasin; Travel; Treatment Outcome

The COVID-19 cases increased very fast in January and February 2020. The mortality among critically ill patients, especially the elder ones, is relatively high. Considering many patients died of severe inflammation response, it is urgent to develop effective therapeutic strategies for these patients. The human umbilical cord mesenchymal stem cells (hUCMSCs) have shown good capabilities to modulate the immune response and repair the injured tissue. Therefore, investigating the potential of hUCMSCs to the treatment of COVID-19 critically ill patients is necessary.. A 65-year-old woman felt fatigued and had a fever with body temperature of 38.2C, coughed up white foaming sputum. After 1 day, she had chest tightness with SPO2 of 81%, and blood pressure of 160/91 mm Hg.. According to the guideline for the diagnosis and treatment of 2019 novel coronavirus infected pneumonia (Trial 4th Edition), COVID-19 was diagnosed, based on the real-time RT-PCR test of SARS-CoV-2.. After regular treatment for 12 days, the inflammation symptom of the patient was still very severe and the potential side effects of corticosteroid were observed. Then, allogenic hUCMSCs were given 3 times (5 × 10 cells each time) with a 3-day interval, together with thymosin α1 and antibiotics daily injection.. After these treatments, most of the laboratory indexes and CT images showed remission of the inflammation symptom. The patient was subsequently transferred out of ICU, and the throat swabs test reported negative 4 days later.. These results indicated the clinical outcome and good tolerance of allogenic hUCMSCs transfer.

Topics: Aged; Anti-Bacterial Agents; Betacoronavirus; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Mesenchymal Stem Cell Transplantation; Pandemics; Pneumonia, Viral; SARS-CoV-2; Thymalfasin; Treatment Outcome

Topics: Adaptive Immunity; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Immunoglobulins, Intravenous; Lymphocyte Activation; Pandemics; Pneumonia, Viral; Protein Precursors; SARS-CoV-2; T-Lymphocytes; Thymalfasin; Thymosin